Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Meningeal Carcinomatosis 1Medulloblastoma 1Desmoplastic Small Round Cell Tumor 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 14Gemcitabine 6Filgrastim 6fludarabine 5Methotrexate 5Leucovorin 5Granulocyte Colony-Stimulating Factor 5Zoledronic Acid 4Temozolomide 4Mesna 4Irinotecan 4Ifosfamide 4Etoposide 4Cisplatin 4Carboplatin 4pembrolizumab 3fludarabine phosphate 3Doxorubicin 3Biopsy 3tanespimycin 2poly ICLC 2pegfilgrastim 2lorukafusp alfa 2liposomal doxorubicin 2dinutuximab 2cabozantinib 2belinostat 2Topotecan 2Thalidomide 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Osteosarcoma × omburtamab I-131 × Clear all
NCT00089245 2023-12-26

Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Y-mAbs Therapeutics

Phase 1 Terminated
177 enrolled
CNSSarcoma

Brain Neoplasms, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Meningeal Carcinomatosis, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡